or Try an Advanced Search...

    TTR Amyloidosis Stocks List

    Symbol Grade Name % Change
    BBIO F BridgeBio Pharma, Inc. -0.32
    IONS F Ionis Pharmaceuticals, Inc. -1.88
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Amyloid Amyloidosis Cardiomyopathy Familial Amyloid Polyneuropathy Myopathy Organ Systems Polyneuropathy Achondroplasia Acromegaly Alcohol Alport Syndrome Angioedema Antisense RNA Apatorsen Cancer Cholesterol Clinical Development Congenital Adrenal Hyperplasia Cushing's Syndrome Diabetes

    Related ETFs - A few ETFs which own one or more of the above listed TTR Amyloidosis stocks.

    Symbol Grade Name Weight
    ARKG F ARK Genomic Revolution Multi-Sector ETF 4.43
    BBP D BioShares Biotechnology Products Fund 3.24
    HELX D Franklin Genomic Advancements ETF 3.03
    WDNA D WisdomTree BioRevolution Fund 2.97
    PBE C PowerShares Dynamic Biotech & Genome 2.67
    View all TTR Amyloidosis ETFs...
    Compare ETFs
    Compare ARKG to WDNA Compare BBP to HELX Compare HELX to PBE

        TTR Amyloidosis Stocks Recent News

        Date Stock Title
        May 8 IONS Ionis Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
        May 8 IONS Q1 2024 Ionis Pharmaceuticals Inc Earnings Call
        May 8 IONS Ionis Pharmaceuticals Inc (IONS) Q1 2024 Earnings Call Transcript Highlights: Key Developments ...
        May 7 IONS Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript
        May 7 IONS Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
        May 7 IONS Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
        May 7 IONS Ionis Pharmaceuticals GAAP EPS of -$0.98 beats by $0.09, revenue of $119M misses by $17.41M
        May 7 IONS Ionis reports first quarter 2024 financial results
        May 6 IONS Ionis Pharmaceuticals Q1 2024 Earnings Preview
        May 6 IONS Wall Street's Insights Into Key Metrics Ahead of Ionis Pharmaceuticals (IONS) Q1 Earnings
        May 4 BBIO What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today
        May 3 BBIO BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations
        May 3 BBIO BridgeBio Oncology Therapeutics launches with $200m funding
        May 2 BBIO BridgeBio Pharma GAAP EPS of -$0.20 beats by $0.31, revenue of $211.12M beats by $127.34M
        May 2 BBIO BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
        May 2 BBIO BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
        May 2 BBIO BridgeBio spinout launches with $200M for KRAS cancer drugs
        Related Industries: Biotechnology
        Related Stock Lists: Amyloid Amyloidosis Cardiomyopathy Familial Amyloid Polyneuropathy Myopathy Organ Systems Polyneuropathy Achondroplasia Acromegaly Alcohol Alport Syndrome Angioedema Antisense RNA Apatorsen Cancer Cholesterol Clinical Development Congenital Adrenal Hyperplasia Cushing's Syndrome Diabetes
        TTR Amyloidosis

        Browse All Tags